Moderna Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Moderna Inc (MRNA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Moderna Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,228M vs 176,724M combined for tracked competitors (1.2% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-74.0% annualized vs trailing 12 months), vs holding steady (+0.0%) for its tracked peer group.
- Growth: Moderna Inc generated 2.1% revenue growth year over year in Q2 2026, vs 5.6% for its tracked competitors combined.
- Profitability: Its -539.3% net margin compares with 4.8% for the peer group.
- Scale: Moderna Inc ranks #3 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 8.8% of industry market cap.
- Peer revenue share: Moderna Inc accounted for 0.3% of combined revenue among its tracked peer group, down from 0.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.47M compares with $0.97M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MRNA Sales vs. its Competitors, Q2 2026
Moderna Inc reported revenue growth of 2.11 % year on year in Q2 2026, below its competitors' combined revenue growth of 5.63 %.
With a net margin of -539.31 %, Moderna Inc reported lower profitability than its competitors (4.83 %).
Moderna Inc generated 0.33 % of the combined sales of its peer group, down from 0.34 % a year earlier.
Moderna Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Moderna Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Moderna Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (15) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Moderna Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 2.1% for Moderna Inc. Moderna Inc's share of combined industry revenue moved from 0.39% to 0.33%, a loss of 0.06 percentage points.
Moderna Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Moderna Inc | No | No | No | Yes |
| Competitors combined (134) | ||||
| High-Confidence Competitors (24) | ||||
| Similar-Size Competitors (7) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) | 50.00 % (4 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MRNA Stock Performance relative to its Competitors
MRNA Stock Performance relative to High-Confidence Competitors
MRNA Stock Performance relative to Similar-Size Competitors
MRNA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 2 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 3 | Absci Corp | 282.9% | Outperformed |
| 4 | Anaptysbio Inc | 282.9% | Outperformed |
| 5 | Immunitybio inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Moderna Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Moderna Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Moderna Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Moderna Inc | 78,517.44 | 2,228.00 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Gsk Plc | 102,307.45 | 32,667.00 |
| Sanofi | 100,940.42 | 52,321.04 |
| SUBTOTAL | 1,616,924.69 | 327,191.66 |
Sign in to see all competitors of Moderna Inc .
Sources: Moderna Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Moderna Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Moderna Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ocugen Inc | Named by the company | 85% |
| Novavax | Named by the company | 85% |
| Oragenics Inc | Named by the company | 85% |
| Canton Strategic Holdings Inc | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Ayala Pharmaceuticals Inc | Named by the company | 85% |
| Generation Bio Co | Named by the company | 85% |
| BioNTech | Named by the company | 85% |
| Telesis Bio Inc | Named by the company | 85% |
| Carisma Therapeutics Inc | Named by the company | 85% |
| Elicio Therapeutics Inc | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
| Pfizer/BioNTech | Named by the company | 85% |
| Q32 Bio Inc | Named by the company | 85% |
| Bionexus Gene Lab Corp | Named by the company | 85% |
| Cue Biopharma Inc | Named by the company | 85% |
| Gridai Technologies Corp | Named by the company | 85% |
| THAR | Named by the company | 85% |
| ENTO | Named by the company | 85% |
| Lineage Cell Therapeutics Inc | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Silexion Therapeutics Corp | Named by the company | 85% |
| Can fite Biopharma Ltd | Named by the company | 85% |
| Dynavax Technologies Corporation | Named by the company | 85% |
| Hillevax Inc | Named by the company | 85% |
| Vaxcyte Inc | Named by the company | 85% |
| Coya Therapeutics Inc | Named by the company | 85% |
| Cocrystal Pharma Inc | Named by the company | 85% |
| Recursion Pharmaceuticals Inc | Named by the company | 85% |
| Gsk Plc | Named by the company | 85% |
| Inovio Pharmaceuticals Inc | Named by the company | 85% |
| Springworks Therapeutics Inc | Named by the company | 85% |
| Geovax Labs Inc | Named by the company | 85% |
| Sunshine Biopharma Inc | Named by the company | 85% |
| Biocardia Inc | Named by the company | 85% |
| Prime Medicine Inc | Named by the company | 85% |
| Vbi Vaccines Inc | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
| Immunitybio inc | Named by the company | 85% |
| Sangamo Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Moderna Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Moderna Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Bridgebio Pharma Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Ionis Pharmaceuticals Inc | Ionis Operations 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Moderna Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Moderna Inc | 78,517 | 474,043 | -670,426 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Gsk Plc | 102,307 | 128,610,236 | 24,759,843 |
| Sanofi | 100,940 | 22,927,713 | 3,853,252 |
| PEERS TOTAL | 1,538,407 | 969,957 | 105,981 |
Moderna Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Pfizer Inc | United States 58.91 % |
| Krystal Biotech Inc | United States 75.19 % |
| Immunitybio inc | United States 98.99 % |
| Nuvation Bio Inc | US 92.98 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Moderna Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Moderna Inc's industry classification, broader than the peer set above. Market cap in millions of $.Moderna Inc ranks #3 of 159 companies by market capitalization in its industry, holding 8.78 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Moderna Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Moderna Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 53.68 % |
| 2 | Gilead Sciences Inc | 185,928 | 34.77 % |
| 3 | Moderna Inc | 76,517 | 681.21 % |
| 4 | Argenx Se | 1,234 | 12.3% |
| 5 | Revolution Medicines Inc | 1,234 | 12.3% |
| 6 | Biogen Inc | 1,234 | 12.3% |
| 7 | Biontech Se | 1,234 | 12.3% |
| 8 | Exelixis Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Moderna Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Moderna Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 23.38 % | 68.46 % (avg) | -45.1 pp |
| Operating Margin | -149.01 % | industry median | +55.9 pp |
| EBITDA Margin | -128.19 % | -0.94 % (avg) | -127.3 pp |
| Capital Intensity (Capex / Revenue) | 7.68 % | 6.74 % (avg) | +0.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Moderna Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 2.8x | 5.1x | -2.3x |
| Return on Equity | -39.20 % | industry aggregate | -35.77 % |
| Return on Invested Capital | -18.84 % | -6.17 % (avg) | -12.67 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Moderna Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 500.00 % | 500.00 % | 4.29 % | -64.45 % | -52.75 % | -39.93 % |
| Operating Margin | - | -4,490.48 % | -94.99 % | 71.98 % | 48.90 % | -61.90 % | -121.91 % | -158.13 % |
| Return on Invested Capital | -48.93 % | 153.88 % | -14.33 % | 72.97 % | 25.13 % | -12.75 % | -15.69 % | -15.41 % |
| P/E | - | - | - | 8.8x | 9.0x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Moderna Inc's Strategic Group Map
Every company in Moderna Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Moderna Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Moderna Inc's BCG Growth-Share Matrix
Relative market share (vs Moderna Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Moderna Inc falls in the Question Mark quadrant: relative market share of 0.34x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Moderna Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 7.68 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Moderna Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Moderna Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Moderna Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Moderna Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Moderna Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 55.9 points above the industry median.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 35.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-74.0% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.34x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (39.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Moderna Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Gsk Plc | - | - | - |
| Sanofi | 0.27 | 1.09 | 0.20 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Moderna Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Sanofi | Q4 2025 | +5.5 % | +39.7 % |
| PEERS TOTAL | +6.3 % | +25.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Moderna Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Sanofi | Q4 2025 | -1.2 % | - |
Moderna Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Moderna Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Sanofi | 6.19% | 8.42% | 10.95% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Moderna Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Moderna Inc | - | 35.24 |
| Johnson and Johnson | 31.48 | 6.78 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Pfizer Inc | 37.66 | 2.57 |
| Gsk Plc | 17.90 | 3.13 |
| Sanofi | 11.43 | 1.93 |
| PEERS AVERAGE | 49.97 | 4.94 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.